Azitra, Inc. Advances Clinical Trial for New Treatment of Dermatologic Toxicities Linked to Cancer Therapies Azitra, Inc. has initiated its Phase 1/2 trial for ATR04-484, targeting skin rashes associated with EGFR inhibitors, addressing a crucial need in oncology.

Azitra, Inc. Advances Clinical Trial for New Treatment of Dermatologic Toxicities Linked to Cancer Therapies #United_States #Azitra #Branford #ATR04-484 #EGFRi

Azitra, Inc. Unveils Groundbreaking ATR-04 Clinical Trial Presentation at ASCO 2025 Azitra, Inc. to present groundbreaking clinical trial results for ATR-04 targeting EGFRi-associated rash at ASCO 2025 in Chicago, showcasing innovative cancer treatment.

Azitra, Inc. Unveils Groundbreaking ATR-04 Clinical Trial Presentation at ASCO 2025 #United_States #Chicago #Azitra #Biomarker #EGFRi